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A re-emerging strategy in the search for disease susceptibility genes is the evaluation of candidate genes,
which are thought to play a role in disease pathogenesis. Candidate genes are screened for single
nucleotide polymorphisms (SNPs) in a case-control study. The factor V Leiden (FVL) mutation (1691G-»A
in the fS gene) is an important risk factor for venous thrombosis. We asked ourselves whether the FVL
mutation would have been found using the candidate gene approach in the absence of prior knowledge of
the haplotype structure of the FS gene. We typed four SNPs in the F5 gene in the Leiden Thrombophilia
study, that is, promoter (99930G->A), exon 13 (55907A-+G), exon 16 (42855A->G), and intron 19
(37833T->G). These SNPs were known to have different population frequencies, making their presence in
distinct haplotypes likely. None of these SNPs has previously been associated with venous thrombotic risk.
Subsequently we derived haplotypes. One haplotype was clearly more frequent in patients than controls
(GAAT; 20 versus 9%), suggesting that a polymorphism in or near the F5 gene in this haplotype is
associated with an increased thrombotic risk. If we had sequenced the F5gene in patients homozygous for
this haplotype, in order to locate the possible causal polymorphism, we would have found that 16 (76%)
patients were homozygous or heterozygous for a missense mutation in exon 10 (1691G ->A), which
predicts the replacement of Arg506 by Gin in one of the cleavage sites for activated protein C, a mutation
that we now know äs the FVL mutation.
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Introduction
The detection of genes underlying complex diseases has
proven to be far more complicated than the detection of
genes associated with diseases with a Mendelian or near-
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Mendelian inheritance. Many studies that reported an
association between a genotype and disease have not been
replicated.1'2 Reasons for this irreproducibility may be a
reduced power of some of the studies because of a small
sample size or the use of subgroup analysis, or multiple
comparisons. Other problems are the small magnitude of
the effect of these genes on disease or the absence of a
hypothesis on a biologic mechanism, which could have
resulted in a measurable intermediate phenotype.3·4
Nevertheless, the attributable risk associated with genes
that have a moderate effect on disease, that is, the fraction
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of the disease risk caused by the allelic Variation in this
gene, may be relatively large when the disease-causing
genotype is common. Risch and Merikangas5 showed that
population-based association studies had more power to
detect such loci than linkage analysis.
Therefore, a re-emerging strategy in the search for disease
susceptibility genes is the evaluation of candidate genes in
population-based association studies. In this approach, the
genotype of several markers in or around the candidate
gene, most often single nucleotide polymorphisms (SNPs),
are studied in unrelated patients and healthy control
subjects. Identification of a candidate gene can be based
on the results from positional cloning, but also on a
hypothesis on the biochemical properties of the encoded
protein and its role in the etiology of the disease. By typing
several SNPs, one can estimate haplotypes of the candidate
gene and establish all the common variants of a gene. The
main hypothesis in the candidate gene approach is that a
relatively common functional variant exists that is still
mainly present in its founder haplotype and that increases
the risk of disease. As a result, the frequency of the founder
haplotype will be increased in the patient population. The
magnitude of this increase is dependent on the risk
associated with the causal polymorphism and on its
frequency in the founder haplotype. Ideally, when Infor-
mation on haplotypes is already available for the gene
under study, one can limit the exercise to those SNPs that
are specific to the existing haplotypes (haplotype-tagging
SNPs). However, when the Information on the haplotype-
structure of a gene is nonexistent or only very limited, äs
was the case for the FS gene, the decision of which SNPs to
determine is dependent on their frequency in the general
population, their degree of linkage disequilibrium and
their position in the gene or, if all the rest is unknown,
only on the latter. By choosing SNPs spread throughout the
gene, of which the rare alleles have nonidentical frequen-
cies between 15 and 50%, the chance of distinguishing
most of the major haplotypes is high. This will increase the
likelihood of finding the haplotype(s) that contain(s) the
causal polymorphism. After identifying a disease-associated
haplotype, one should subsequently sequence (preferably
homozygous) carriers of this haplotype to identify
additional SNPs that are specific to this haplotype or that
contribute to a subhaplotype. By selecting homo-
zygous patients, the chance of finding such SNPs is
maximized.
Deep venous thrombosis is a multicausal disease. Several
genetic äs well äs acquired risk factors have been described
that contribute to the risk of venous thrombosis, which is
thought to result from specific interaction between genes
and environment.6 Until 1993, only a minority of
thrombosis patients was found to carry one of the genetic
risk factors known at that time. In 1993, Dahlbäck et al7
described a new mechanism for thrombosis that was
characterized by the laboratory phenotype of a poor
anticoagulant response to activated protein C (APC
resistance). In 1994, we described a mutation in the factor
V gene (G-»A Substitution at nucleotide position 1691 in
the cDNA), which predicts the synthesis of a factor V
molecule that is less efficiently downregulated by APC, and
thus explains the laboratory phenotype of APC resistance.8
The factor V Leiden (FVL) mutation has been associated
with a three- to eight-fold increased risk of venous
thrombosis. The prevalence of this mutation ranges
between 3 and 7% in Caucasian populations with large
regional differences. Several studies reported on a haplo-
type in the factor V gene that was associated with the FVL
mutation, thus providing evidence for a single origin of
this mutation.9^13
We now asked ourselves whether the FVL mutation
would have been found by evaluating FS äs a candidate
gene in a population-based association study using a case-
control design. This study was therefore performed without
knowing beforehand who carried the FVL mutation, and
who did not, and without taking the limited haplotype
Information on this gene into account.
Patients and methods
Selection of a candidate gene can be based on the
biochemical properties of the encoded protein. Coagula-
tion factor V, which plays an essential role in blood
coagulation, is äs such an obvious candidate in an
investigation of the etiology of venous thrombosis. It is
together with factor VIII, the only physiological Substrate
of APC. The gene for human factor V (FS) is localized on
chromosome lq23-24, and consists of 25 exons and 24
introns.14 The size of the factor V gene is 75 kb (Figure 1).

















Figure l Schematic representation of the genomic region of the factor V gene. The gene is shown approximately to scale;
the relative sizes of the exons, shown below the line, are indicated by the thickness of the lines. The approximate position of
the SNPs and their exact coordinates in CenBank: Z99572 are shown above the line. F5= factor V gene; SELP = P-selectin
gene. Numbers below the line refer to exon numbers.
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Since, during the performance of this study, very little
Information was available with respect to the general
haplotype structure of the factor V gene, SNPs were chosen
based on their high frequency in the Dutch population
(15-50% for the rare allele) and their position in the gene.
By choosing SNPs spread throughout the gene, of which
the rare alleles have nonidentical frequencies between 15
and 50%, the chance of distinguishing most of the major
haplotypes is high. We determined a SNP in the promoter
region (99930G^A), in exon 13 (55907A^G), in exon 16
(42855A-*G), and in intron 19 (37833T->G) (numbering
according to GenBank: Z99572).
This study was performed in 474 unselected patients
with a first deep venous thrombosis and 474 unrelated
controls from the Leiden Thrombophilia Study (LETS).15
The control subjects came from the same geographical area
äs the patients.
The risk of venous thrombosis was calculated for each
SNP individually by calculating odds ratios (OR) and their
95% confidence intervals (95% CI). Furthermore, using
Arlequin, a Software program for population genetics,16 we
estimated the haplotype frequencies in patients and
control subjects. With this program, maximum-likelihood
haplotype frequencies are computed using an expectation-
maximization (EM) algorithm.17
Results and discussion
The genotypes for all four SNPs could be determined by
polymerase chain reaction (PCR) in 471 patients and 472
control subjects. Of these four polymorphisms, the SNPs in
exons 13, 16 and intron 19 were in linkage disequilibrium
(exons 13 and 16: Δ = 0.90; exon 13 and intron 19:
Δ = 0.67; exon 16 and intron 19: Δ = 0.74).
In Table l the venous thrombotic risk associated with the
less frequent allele of each SNP is shown. The SNPs in the
promoter region and exons 13 and 16 were itself not
associated with an increased risk of venous thrombosis,
that is, carriership of the rare allele of these SNPs is at most
associated with a weakly protective effect. Individuais
homozygous for the less frequent allele of the SNP in
intron 19 (T allele) had a weakly increased risk of venous
thrombosis compared with individuals homozygous for
the G allele (OR=1.4; 95% CI: 1.0-2.1).
Using Arlequin, a Software program for population
genetics,16 we subsequently estimated the haplotype
frequencies in patients and control subjects. In Table 2,
the frequencies in both patients and control subjects are
shown for all haplotypes with a frequency of more than 1%
in the total population of both patients and control
subjects (LETS). In total, 11 of the 16 possible haplotypes
were found in this study population, seven of which had a
frequency of more than 1%. The haplotype distribution in
patients and control subjects was significantly different (χ2:
26.0, df: 10, P-value: 0.004).
As shown in Table 2, there was one haplotype that was
clearly more frequent in patients compared with control
subjects (GAAT; 20% in patients versus 9% in control
subjects). This finding suggests that a polymorphism in or
near the factor V gene in this haplotype is associated with
Table 1 The risk of deep venous thrombosis associated with several SNPs in the factor V gene
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aOrder of the SNPs in the table is: promoter C99930A, exon 13 A55907G, exon 16 A42855G, intron 19 T37833G.
an increased risk of venous thrombosis, that is, could be
the causal variant, and thus causes a higher frequency of
this haplotype in patients. Consequently, the frequency of
some of the other haplotypes is slightly lower in patients
compared with the control subjects. This explains the
weakly protective effect of some of the polymorphisms
described in Table 1.
In all, 21 patients and seven control subjects were
homozygous for the GAAT-haplotype. If we had sequenced
the factor V gene in all these patients in order to locate the
possible causal polymorphism, we would have found that
16 (76%) patients were homozygous (n = 7) or heterozy-
gous (n = 9) for a so far unknown missense mutation in
exon 10 (1691G->A), which predicts the replacement of
Arg 506 by Gin in one of the cleavage sites for activated
protein C, a mutation, that we now know äs the FVL
mutation. Probably, also other sequence variations would
have been found during the sequencing of the factor V
genes of these subjects. However, the fact that this mutation
affects one of the cleavage sites for activated protein C
would have made this missense mutation a likely candidate
for being the functional mutation, and thus one of the first
mutations that would be investigated in more detail.
The SNPs in exons 13 and 16 were in strong linkage
disequilibrium. The construction of haplotypes using only
the SNPs in the promoter, intron 19 and either exon 13 or
16 would also have led to the discovery of a haplotype that
was clearly more frequent in patients than in control
subjects (eg, Prom-exon 13-intron 19: GAT patients:
23.9%, controls subjects: 12.8%).
As mentioned above, in a multicausal disease such äs
deep venous thrombosis, in which more than one risk
factor needs to be present to cause the disease, highly
prevalent, weak to moderate risk factors may occur, äs well
äs numerous rare, very strong risk factors. The latter are
more likely to be found using linkage analysis.
Clearly, more genetic risk factors will be discovered in
the future, especially since in about 30% of patients with a
family history of the disease äs yet no (genetic) risk factor
has been found.
We now demonstrate that an earlier discovered common
risk factor for venous thrombosis, that is, the FVL
mutation, would indeed have been found using popula-
tion-based association studies with a case-control design.
Recently, in the study of risk factors for venous thrombosis,
the pros and cons of association studies versus linkage
analysis have been debated.18'19 Following the candidate
gene approach in an association study, prevalent risk
factors associated with a moderate increase in the risk
of thrombosis can be found that are unlikely to be
found using linkage analysis due to a lack of power of the
latter studies.
The chance of finding a causal mutation with the
candidate gene approach depends on the number of
patients (Npat) and control subjects (Ncon), the risk
associated with the mutation (ORmut), and the frequency
of the mutation in the general population (fmut)· Under the
assumption that a causal mutation exists only in one
(founder) haplotype, one can calculate the maximum
frequency (fmax) of this (founder) haplotype in the general
population, with which it is still possible to detect an
increased risk associated with this haplotype. In general,
since it is unknown beforehand which haplotype contains
the causal mutation, the frequency of the most common
haplotype should not exceed fmax.
In this study (i.e., Npat = Ncon = 474, ORmut = 6,
fmut = 4%), we can calculate that fmax = 64%. As shown in
Table 2, the frequency of the most common haplotype
equals 47%. Thus, we would have been able to find the
FVL mutation in this study. Note that in a smaller study,
more SNPs would be needed to split the most frequent
haplotype into smaller groups (eg, when Npat = N"con = 100,
fmax = 23%).
Several known genetic variations, for example, the FVL
mutation and the prothrombin G20210A mutation, each
appear to be the product of a unique mutational event in a
founder haplotype,9"13'20 validating the above assump-
tion. Dominant gain-of-function mutations such äs these
are likely to be found using the candidate gene approach,
and we consider it likely that many more such disease-
causing mutations exist in the human gene pool.
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